Coversyl: Effective Blood Pressure Control for Cardiovascular Health
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.38 | $41.28 (0%) | 🛒 Add to cart |
| 60 | $1.20 | $82.56 $72.24 (13%) | 🛒 Add to cart |
| 90 | $1.03 | $123.84 $92.88 (25%) | 🛒 Add to cart |
| 120 | $0.99 | $165.12 $118.68 (28%) | 🛒 Add to cart |
| 180 | $0.95 | $247.68 $170.28 (31%) | 🛒 Add to cart |
| 270 | $0.77 | $371.52 $208.98 (44%) | 🛒 Add to cart |
| 360 | $0.69
Best per pill | $495.36 $247.68 (50%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $1.72 | $34.40 (0%) | 🛒 Add to cart |
| 30 | $1.46 | $51.60 $43.86 (15%) | 🛒 Add to cart |
| 60 | $1.29 | $103.20 $77.40 (25%) | 🛒 Add to cart |
| 90 | $1.15 | $154.80 $103.20 (33%) | 🛒 Add to cart |
| 120 | $1.03 | $206.40 $123.84 (40%) | 🛒 Add to cart |
| 180 | $0.99 | $309.60 $178.02 (42%) | 🛒 Add to cart |
| 270 | $0.95 | $464.40 $255.42 (45%) | 🛒 Add to cart |
| 360 | $0.86
Best per pill | $619.20 $309.60 (50%) | 🛒 Add to cart |
| Product dosage: 8mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.58 | $51.60 (0%) | 🛒 Add to cart |
| 30 | $2.41 | $77.40 $72.24 (7%) | 🛒 Add to cart |
| 60 | $2.24 | $154.80 $134.16 (13%) | 🛒 Add to cart |
| 90 | $2.06 | $232.20 $185.76 (20%) | 🛒 Add to cart |
| 120 | $1.89 | $309.60 $227.04 (27%) | 🛒 Add to cart |
| 180 | $1.72 | $464.40 $309.60 (33%) | 🛒 Add to cart |
| 270 | $1.46 | $696.60 $394.74 (43%) | 🛒 Add to cart |
| 360 | $1.29
Best per pill | $928.80 $464.40 (50%) | 🛒 Add to cart |
Coversyl (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor prescribed for the management of hypertension and heart failure. As a first-line therapeutic option, it functions by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation and reducing peripheral arterial resistance. Its proven efficacy in large-scale clinical trials has established it as a cornerstone in cardiovascular risk reduction strategies, offering both hemodynamic benefits and potential end-organ protection.
Features
- Active pharmaceutical ingredient: Perindopril arginine or Perindopril erbumine
- Standard tablet strengths: 2.5 mg, 5 mg, 8 mg, 10 mg
- Administration: Oral, once-daily dosing
- Mechanism: Competitive inhibition of angiotensin-converting enzyme (ACE)
- Bioavailability: Approximately 65–75% for perindopril, with conversion to active metabolite perindoprilat
- Half-life: Perindoprilat exhibits a prolonged elimination half-life of 30–120 hours
- Excretion: Primarily renal (75%), with some fecal elimination
Benefits
- Provides sustained 24-hour blood pressure control with single daily dosing, supporting adherence
- Reduces afterload and preload in heart failure, improving cardiac output and functional capacity
- Demonstrates evidence of slowing the progression of atherosclerotic plaque in certain patient populations
- May offer nephroprotective effects in hypertensive patients with diabetes by reducing intraglomerular pressure
- Associated with regression of left ventricular hypertrophy, an independent risk factor for cardiovascular events
- Contributes to overall cardiovascular risk reduction beyond blood pressure lowering alone
Common use
Coversyl is indicated for the treatment of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also approved for the management of stable coronary artery disease and chronic heart failure (NYHA Class I–IV), particularly as part of a comprehensive treatment plan. In clinical practice, it is frequently utilized in patients with concomitant type 2 diabetes due to its favorable metabolic profile and potential renal benefits. Off-label uses may include secondary stroke prevention and management of certain forms of diabetic nephropathy, though these require specialist supervision.
Dosage and direction
The initial dosage for hypertension typically begins at 4 mg once daily, which may be increased to 8 mg after one month based on therapeutic response. For elderly patients or those with renal impairment, a starting dose of 2 mg is recommended. In heart failure, therapy should be initiated under close medical supervision at 2 mg daily, titrated gradually to a maximum of 8 mg based on tolerability. Administration should occur at approximately the same time each day, with or without food, though consistency is advised. Tablets must be swallowed whole and not crushed or chewed. Dosage adjustments are necessary in patients with creatinine clearance below 60 mL/min, with specific guidelines provided in the prescribing information.
Precautions
Patients should be monitored for hypotension, particularly following the initial dose and after dosage increases. Renal function and serum potassium levels require assessment prior to initiation and periodically during therapy, especially in patients with pre-existing renal impairment, diabetes, or those concomitantly using potassium-sparing diuretics. A baseline white blood cell count is advisable in patients with collagen vascular disease or those receiving immunosuppressive therapy due to the risk of neutropenia. Use with caution in patients with aortic stenosis or hypertrophic cardiomyopathy. Angioedema has been reported with ACE inhibitors, requiring immediate discontinuation and emergency management if involving the tongue, glottis, or larynx.
Contraindications
Coversyl is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy. It must not be used during pregnancy, particularly in the second and third trimesters, due to the risk of fetal injury and death. Additional contraindications include bilateral renal artery stenosis, hypersensitivity to perindopril or any other ACE inhibitor, and concomitant use with aliskiren in patients with diabetes. It is not recommended in patients with hereditary or idiopathic angioedema.
Possible side effects
The most frequently reported adverse reactions include persistent dry cough (up to 12% of patients), dizziness (4–8%), headache (5–7%), and fatigue (3–5%). Less common but clinically significant effects may include orthostatic hypotension, hyperkalemia, renal impairment, angioedema, and taste disturbances. Rare cases of neutropenia/agranulocytosis, pancreatitis, and hepatic enzyme elevations have been reported. Cutaneous reactions such as rash and photosensitivity occur infrequently. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.
Drug interaction
Concomitant use with diuretics may potentiate hypotensive effects, particularly following the first dose. NSAIDs may reduce the antihypertensive efficacy of Coversyl and increase the risk of renal impairment. Potassium supplements or potassium-sparing diuretics increase the risk of hyperkalemia. Lithium levels may increase due to reduced renal clearance. Dual blockade of the renin-angiotensin system with ARBs or aliskiren is not recommended due to increased risks of hypotension, hyperkalemia, and renal impairment. Antidiabetic agents may require dosage adjustment as ACE inhibitors can enhance hypoglycemic effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to compensate for a missed administration. Consistent daily adherence is important for maintaining stable blood pressure control, and patients should be educated on establishing routine medication habits.
Overdose
Manifestations of overdose primarily include pronounced hypotension, which may progress to shock. Bradycardia, electrolyte disturbances, and renal failure may occur. Management involves immediate cardiovascular support, including volume expansion with intravenous normal saline and vasopressors if necessary. Perindopril is not effectively removed by hemodialysis due to high protein binding, though dialysis may be considered for managing associated electrolyte imbalances. Gastric lavage may be beneficial if performed shortly after ingestion. Continuous hemodynamic monitoring in an intensive care setting is essential.
Storage
Store at room temperature (15–30°C or 59–86°F) in the original container, protected from light and moisture. Keep the bottle tightly closed and away from excessive heat or humidity. Do not store in bathrooms or near kitchen sinks. Keep out of reach of children and pets. Do not use tablets that show signs of discoloration, cracking, or other physical deterioration. Properly discard any unused medication after the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions must be made by a qualified healthcare professional based on individual patient characteristics. Always consult the official prescribing information and latest clinical guidelines before initiating therapy. Dosage and administration may vary based on specific patient factors, including age, renal function, and concomitant medications. Patients should not alter their treatment regimen without consulting their physician.
Reviews
Clinical studies, including the EUROPA and ASCOT trials, have demonstrated Coversyl’s efficacy in reducing cardiovascular events in hypertensive patients. Meta-analyses of ACE inhibitors consistently show significant reductions in stroke, myocardial infarction, and heart failure hospitalization. Patient-reported outcomes often note improved blood pressure control and quality of life, though the characteristic dry cough remains a frequent reason for discontinuation. Long-term observational data support its sustained effectiveness and safety profile in diverse patient populations over treatment periods exceeding ten years.